RBC Capital Maintains Outperform on ADC Therapeutics, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on ADC Therapeutics (NYSE:ADCT) and increased the price target from $6 to $8.
February 26, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza reaffirmed an Outperform rating on ADC Therapeutics and raised the price target from $6 to $8.
The increase in price target by a reputable analyst like Gregory Renza suggests a positive outlook on ADC Therapeutics' stock, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100